Cost-Effectiveness of Almotriptan and Rizatriptan in the Treatment of Acute Migraine

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2903-2919

  Williams, Paul ^a   Reeder, C E ^b  

^a PAREXEL INTERNATIONAL   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Almotriptan; Cost effectiveness; Migraine; Rizatriptan; Triptans

Indexed keywords

ALMOTRIPTAN; RIZATRIPTAN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; MIGRAINE; MODEL;

EID: 0345095460     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80344-2     Document Type: Article

References (23)

1. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813-818.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270.
3. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
4. Dodick DW, Lipton RB, Goadsby PJ, et al. Prioritizing triptan treatment attributes: A pilot study. Neurology. 2002;58(Suppl 3):A129. Abstract.
5. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
6. Dodick D, Cutrer FM, Ferrari M, et al. Prioritization of treatment attributes in selecting an oral triptan: A survey of US neurologists. Headache. 2002;42:392. Abstract.
7. Cutrer FM, Goadsby PJ, Ferrari M, et al. Prioritization of treatment attributes in selecting an oral triptan: A survey of US primary care physicians. Headache. 2002;42:392-393. Abstract.
8. Lipton RB, Liberman J, Goadsby PJ, et al. An assessment of the priorities of US migraineurs with respect to prespecified triptan treatment attributes. Headache. 2002;42:394-395. Abstract.
9. McCrory D, Williams P. Selecting the preferred triptans. Cephalalgia. 2002;22:575. Abstract.
10. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure': Number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol. 1996;25:704-712.
11. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
12. Roon KI, Lipton RB, Goadsby PJ, Ferrari MD. Placebo in triptan trials: Efficacy, tolerability and consistency. Cephalalgia. 2001;21:405-406. Abstract.
13. First DataBank. Price Probe [database on CD-ROM]. San Bruno, Calif: First DataBank; 2003. Updated March 2003.
14. Luttinen RT. Uncertainty in the operational analysis of two-lane highways. Available at: http://www.tiehallinto.fi/s12/htdocs/photo/julkaisut/ wash_luttinen.pdf. Accessed August 11, 2003.
15. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
16. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 1986;6:85-92.
17. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
18. Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache. 1999;39(Suppl 2):S20-S26.
19. Oxford Centre for Evidence-based Medicine levels of evidence. Available at: http://www.cebm.net/downloads/Oxford_CEBM_Levels_5.rtf. Accessed October 22, 2003.
20. Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: Implications for managed care. Am J Manag Care. 2002;8(Suppl 3):S80-S84.
21. Gerth WC, Adelman JU, McCarroll KA. Cost per success comparison of rizatriptan and other triptans based on a stringent measure of efficacy. Cephalalgia. 2001;21:340-341. Abstract.
22. Rothermich EA, Levaux HP, Colman S, et al. Economic analysis of acute migraine: Results from a controlled comparison of almotriptan and sumatriptan. Cephalalgia. 2001;21:341. Abstract.
23. Wells NE. A cost-effectiveness analysis of eletriptan 40 mg and 80 mg vs sumatriptan 50 mg and 100 mg in the treatment of migraine attacks. Cephalalgia. 2001;21:341. Abstract.